annual CFF:
-$4.00B+$2.57B(+39.15%)Summary
- As of today (May 29, 2025), AZN annual cash flow from financing activities is -$4.00 billion, with the most recent change of +$2.57 billion (+39.15%) on December 31, 2024.
- During the last 3 years, AZN annual CFF has fallen by -$7.64 billion (-209.51%).
- AZN annual CFF is now -166.04% below its all-time high of $6.05 billion, reached on December 31, 2007.
Performance
AZN Cash from financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFF:
-$2.71B-$2.04B(-303.43%)Summary
- As of today (May 29, 2025), AZN quarterly cash flow from financing activities is -$2.71 billion, with the most recent change of -$2.04 billion (-303.43%) on March 31, 2025.
- Over the past year, AZN quarterly CFF has dropped by -$4.74 billion (-233.48%).
- AZN quarterly CFF is now -122.18% below its all-time high of $12.21 billion, reached on June 30, 2007.
Performance
AZN quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
-$8.73B-$4.74B(-118.49%)Summary
- As of today (May 29, 2025), AZN TTM cash flow from financing activities is -$8.73 billion, with the most recent change of -$4.74 billion (-118.49%) on March 31, 2025.
- Over the past year, AZN TTM CFF has dropped by -$6.22 billion (-248.13%).
- AZN TTM CFF is now -230.39% below its all-time high of $6.70 billion, reached on March 31, 2008.
Performance
AZN TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
AZN Cash from financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +39.1% | -233.5% | -248.1% |
| 3 y3 years | -209.5% | +27.6% | -430.7% |
| 5 y5 years | -126.4% | -14.6% | -154.6% |
AZN Cash from financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -209.5% | +41.4% | -233.5% | +34.5% | -430.7% | at low |
| 5 y | 5-year | -209.5% | +41.4% | -137.1% | +34.5% | -339.3% | at low |
| alltime | all time | -166.0% | +57.1% | -122.2% | +34.5% | -230.4% | +7.7% |
AZN Cash from financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$2.71B(+303.4%) | -$8.73B(+118.5%) |
| Dec 2024 | -$4.00B(-39.2%) | -$671.00M(-83.8%) | -$4.00B(+10.5%) |
| Sep 2024 | - | -$4.13B(+238.1%) | -$3.62B(+63.5%) |
| Jun 2024 | - | -$1.22B(-160.3%) | -$2.21B(-11.8%) |
| Mar 2024 | - | $2.03B(-796.9%) | -$2.51B(-61.8%) |
| Dec 2023 | -$6.57B(-3.8%) | -$291.00M(-89.3%) | -$6.57B(-1.0%) |
| Sep 2023 | - | -$2.73B(+79.5%) | -$6.63B(+24.3%) |
| Jun 2023 | - | -$1.52B(-25.2%) | -$5.34B(+4.4%) |
| Mar 2023 | - | -$2.03B(+467.3%) | -$5.11B(-25.0%) |
| Dec 2022 | -$6.82B(-287.0%) | -$358.00M(-75.0%) | -$6.82B(-9.2%) |
| Sep 2022 | - | -$1.43B(+10.4%) | -$7.52B(+26.4%) |
| Jun 2022 | - | -$1.29B(-65.4%) | -$5.94B(-325.2%) |
| Mar 2022 | - | -$3.74B(+255.9%) | $2.64B(-27.7%) |
| Dec 2021 | $3.65B(-265.6%) | -$1.05B(-840.1%) | $3.65B(+46.5%) |
| Sep 2021 | - | $142.00M(-98.1%) | $2.49B(-30.7%) |
| Jun 2021 | - | $7.29B(-366.9%) | $3.59B(-239.6%) |
| Mar 2021 | - | -$2.73B(+23.6%) | -$2.57B(+16.7%) |
| Dec 2020 | -$2.20B(+24.8%) | -$2.21B(-277.8%) | -$2.20B(<-9900.0%) |
| Sep 2020 | - | $1.24B(+10.4%) | $13.00M(-100.3%) |
| Jun 2020 | - | $1.13B(-147.7%) | -$3.94B(+15.0%) |
| Mar 2020 | - | -$2.36B(<-9900.0%) | -$3.43B(+94.3%) |
| Dec 2019 | -$1.76B(-13.6%) | $6.00M(-100.2%) | -$1.76B(-49.6%) |
| Sep 2019 | - | -$2.71B(-265.5%) | -$3.50B(+463.2%) |
| Jun 2019 | - | $1.64B(-334.8%) | -$622.00M(-70.1%) |
| Mar 2019 | - | -$698.00M(-59.7%) | -$2.08B(+1.7%) |
| Dec 2018 | -$2.04B(-30.4%) | -$1.73B(-1124.9%) | -$2.04B(+530.9%) |
| Sep 2018 | - | $169.00M(-7.1%) | -$324.00M(-90.9%) |
| Jun 2018 | - | $182.00M(-127.5%) | -$3.56B(+128.8%) |
| Mar 2018 | - | -$663.00M(+5425.0%) | -$1.56B(-47.0%) |
| Dec 2017 | -$2.94B(+121.8%) | -$12.00M(-99.6%) | -$2.94B(-9.0%) |
| Sep 2017 | - | -$3.07B(-240.3%) | -$3.23B(+175.4%) |
| Jun 2017 | - | $2.19B(-207.1%) | -$1.17B(-41.5%) |
| Mar 2017 | - | -$2.04B(+571.7%) | -$2.00B(+51.4%) |
| Dec 2016 | -$1.32B(-250.8%) | -$304.00M(-70.0%) | -$1.32B(-140.6%) |
| Sep 2016 | - | -$1.01B(-174.8%) | $3.26B(+0.1%) |
| Jun 2016 | - | $1.35B(-199.6%) | $3.26B(+56.3%) |
| Mar 2016 | - | -$1.36B(-131.8%) | $2.09B(+137.6%) |
| Dec 2015 | $878.00M(-132.5%) | $4.28B(-520.8%) | $878.00M(-138.9%) |
| Sep 2015 | - | -$1.02B(-662.4%) | -$2.25B(-10.6%) |
| Jun 2015 | - | $181.00M(-107.0%) | -$2.52B(-17.6%) |
| Mar 2015 | - | -$2.57B(-323.2%) | -$3.06B(+13.2%) |
| Dec 2014 | -$2.71B(-11.2%) | $1.15B(-189.5%) | -$2.71B(-26.0%) |
| Sep 2014 | - | -$1.29B(+259.2%) | -$3.65B(+5.0%) |
| Jun 2014 | - | -$358.00M(-83.8%) | -$3.48B(+15.0%) |
| Mar 2014 | - | -$2.21B(-1200.5%) | -$3.03B(-0.7%) |
| Dec 2013 | -$3.05B(-38.1%) | $201.00M(-118.1%) | -$3.05B(-19.2%) |
| Sep 2013 | - | -$1.11B(-1258.3%) | -$3.77B(+30.0%) |
| Jun 2013 | - | $96.00M(-104.3%) | -$2.90B(-21.9%) |
| Mar 2013 | - | -$2.23B(+325.1%) | -$3.72B(-24.5%) |
| Dec 2012 | -$4.92B(-47.2%) | -$525.00M(+116.9%) | -$4.92B(-19.0%) |
| Sep 2012 | - | -$242.00M(-66.3%) | -$6.08B(-30.0%) |
| Jun 2012 | - | -$718.00M(-79.1%) | -$8.69B(-3.0%) |
| Mar 2012 | - | -$3.44B(+104.5%) | -$8.95B(-4.0%) |
| Dec 2011 | -$9.32B | -$1.68B(-41.0%) | -$9.32B(-1.5%) |
| Sep 2011 | - | -$2.85B(+189.9%) | -$9.46B(+13.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2011 | - | -$983.00M(-74.2%) | -$8.34B(+6.9%) |
| Mar 2011 | - | -$3.81B(+109.2%) | -$7.80B(+6.4%) |
| Dec 2010 | -$7.33B(+102.1%) | -$1.82B(+5.1%) | -$7.33B(+34.6%) |
| Sep 2010 | - | -$1.73B(+289.0%) | -$5.45B(+5.0%) |
| Jun 2010 | - | -$445.00M(-86.7%) | -$5.19B(+10.1%) |
| Mar 2010 | - | -$3.34B(-5315.6%) | -$4.71B(+29.9%) |
| Dec 2009 | -$3.63B(-43.0%) | $64.00M(-104.4%) | -$3.63B(-29.6%) |
| Sep 2009 | - | -$1.47B(-4841.9%) | -$5.16B(-14.5%) |
| Jun 2009 | - | $31.00M(-101.4%) | -$6.03B(-3.1%) |
| Mar 2009 | - | -$2.25B(+54.1%) | -$6.22B(-2.2%) |
| Dec 2008 | -$6.36B(-205.1%) | -$1.46B(-37.6%) | -$6.36B(+24.9%) |
| Sep 2008 | - | -$2.35B(+1374.8%) | -$5.09B(-10.1%) |
| Jun 2008 | - | -$159.00M(-93.4%) | -$5.67B(-184.6%) |
| Mar 2008 | - | -$2.40B(+1134.5%) | $6.70B(+10.7%) |
| Dec 2007 | $6.05B(-212.8%) | -$194.00M(-93.4%) | $6.05B(+18.9%) |
| Sep 2007 | - | -$2.92B(-123.9%) | $5.09B(-16.8%) |
| Jun 2007 | - | $12.21B(-501.5%) | $6.12B(-190.5%) |
| Mar 2007 | - | -$3.04B(+163.4%) | -$6.76B(+26.1%) |
| Dec 2006 | -$5.37B(+17.4%) | -$1.15B(-38.9%) | -$5.37B(+8.1%) |
| Sep 2006 | - | -$1.89B(+177.4%) | -$4.96B(+6.1%) |
| Jun 2006 | - | -$681.00M(-58.5%) | -$4.68B(+0.6%) |
| Mar 2006 | - | -$1.64B(+118.4%) | -$4.65B(+1.7%) |
| Dec 2005 | -$4.57B(+65.6%) | -$752.00M(-53.1%) | -$4.57B(+2.5%) |
| Sep 2005 | - | -$1.60B(+144.7%) | -$4.46B(+14.0%) |
| Jun 2005 | - | -$655.00M(-58.1%) | -$3.91B(+4.6%) |
| Mar 2005 | - | -$1.56B(+143.7%) | -$3.74B(+35.6%) |
| Dec 2004 | -$2.76B(+3.3%) | -$641.00M(-39.3%) | -$2.76B(-36.6%) |
| Sep 2004 | - | -$1.06B(+118.2%) | -$4.36B(+39.1%) |
| Jun 2004 | - | -$484.00M(-16.6%) | -$3.13B(-0.2%) |
| Mar 2004 | - | -$580.00M(-74.1%) | -$3.14B(+17.3%) |
| Dec 2003 | -$2.67B(-19.3%) | -$2.24B(-1418.9%) | -$2.67B(-7.1%) |
| Sep 2003 | - | $169.68M(-134.7%) | -$2.88B(+55.2%) |
| Jun 2003 | - | -$489.49M(+321.3%) | -$1.85B(-43.7%) |
| Mar 2003 | - | -$116.19M(-95.2%) | -$3.30B(-0.5%) |
| Dec 2002 | -$3.31B(+71.2%) | -$2.44B(-304.6%) | -$3.31B(+160.4%) |
| Sep 2002 | - | $1.19B(-161.9%) | -$1.27B(-50.1%) |
| Jun 2002 | - | -$1.93B(+1351.1%) | -$2.55B(+34.1%) |
| Mar 2002 | - | -$133.00M(-67.0%) | -$1.90B(-1.8%) |
| Dec 2001 | -$1.94B(+383.4%) | -$403.00M(+391.5%) | -$1.94B(+21.5%) |
| Sep 2001 | - | -$82.00M(-93.6%) | -$1.59B(+1.1%) |
| Jun 2001 | - | -$1.28B(+665.9%) | -$1.58B(+276.3%) |
| Mar 2001 | - | -$167.46M(+174.9%) | -$418.93M(+4.7%) |
| Dec 2000 | -$400.29M(-75.8%) | -$60.91M(-6.8%) | -$400.29M(+17.9%) |
| Sep 2000 | - | -$65.34M(-47.8%) | -$339.38M(+23.8%) |
| Jun 2000 | - | -$125.23M(-15.8%) | -$274.04M(+84.2%) |
| Mar 2000 | - | -$148.81M | -$148.81M |
| Dec 1999 | -$1.65B(+631.0%) | - | - |
| Dec 1998 | -$226.00M(+327.2%) | - | - |
| Dec 1997 | -$52.90M(-20.8%) | - | - |
| Dec 1996 | -$66.79M(-190.0%) | - | - |
| Dec 1995 | $74.17M(-109.2%) | - | - |
| Dec 1994 | -$805.15M(-219.9%) | - | - |
| Dec 1993 | $671.56M(+638.0%) | - | - |
| Dec 1992 | $91.00M(-134.7%) | - | - |
| Dec 1991 | -$261.97M(-52.8%) | - | - |
| Dec 1990 | -$555.53M | - | - |
FAQ
- What is AstraZeneca annual cash flow from financing activities?
- What is the all time high annual CFF for AstraZeneca?
- What is AstraZeneca annual CFF year-on-year change?
- What is AstraZeneca quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for AstraZeneca?
- What is AstraZeneca quarterly CFF year-on-year change?
- What is AstraZeneca TTM cash flow from financing activities?
- What is the all time high TTM CFF for AstraZeneca?
- What is AstraZeneca TTM CFF year-on-year change?
What is AstraZeneca annual cash flow from financing activities?
The current annual CFF of AZN is -$4.00B
What is the all time high annual CFF for AstraZeneca?
AstraZeneca all-time high annual cash flow from financing activities is $6.05B
What is AstraZeneca annual CFF year-on-year change?
Over the past year, AZN annual cash flow from financing activities has changed by +$2.57B (+39.15%)
What is AstraZeneca quarterly cash flow from financing activities?
The current quarterly CFF of AZN is -$2.71B
What is the all time high quarterly CFF for AstraZeneca?
AstraZeneca all-time high quarterly cash flow from financing activities is $12.21B
What is AstraZeneca quarterly CFF year-on-year change?
Over the past year, AZN quarterly cash flow from financing activities has changed by -$4.74B (-233.48%)
What is AstraZeneca TTM cash flow from financing activities?
The current TTM CFF of AZN is -$8.73B
What is the all time high TTM CFF for AstraZeneca?
AstraZeneca all-time high TTM cash flow from financing activities is $6.70B
What is AstraZeneca TTM CFF year-on-year change?
Over the past year, AZN TTM cash flow from financing activities has changed by -$6.22B (-248.13%)